Catherine A. Eberlein

CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma

Colin W. Steele, Saadia A. Karim, Joshua D.G. Leach et al. · Cancer Cell · 2016 · 838 citations · Full text

Medicine, Cancer Biology, Oncology +17

Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models

Catherine A. Eberlein, Daniel Stetson, Aleksandra Markovets et al. · Cancer Research · 2015 · 300 citations · Full text

Medicine, Oncology, Pharmacology +17

A human monoclonal antibody 264RAD targeting αvβ6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivo

Catherine A. Eberlein, Jane Kendrew, Karen McDaid et al. · Oncogene · 2012 · 86 citations

Medicine, Cancer Biology, Oncology +17

E-Cadherin and EpCAM expression by NSCLC tumour cells associate with normal fibroblast activation through a pathway initiated by integrin αvβ6 and maintained through TGFβ signalling

Catherine A. Eberlein, Claire Rooney, Sarah J. Ross et al. · Oncogene · 2014 · 59 citations

Life Sciences, Cell Biology, Oncology +15

Combined Inhibition of PI3Kβ and mTOR Inhibits Growth of PTEN-null Tumors

James T. Lynch, Urszula M. Polanska, Ursula Hancox et al. · Molecular Cancer Therapeutics · 2018 · 27 citations

Medicine, Oncology, Pharmacology +16